Stay updated on KarXT Efficacy in Acute Schizophrenic Patients Clinical Trial
Sign up to get notified when there's something new on the KarXT Efficacy in Acute Schizophrenic Patients Clinical Trial page.

Latest updates to the KarXT Efficacy in Acute Schizophrenic Patients Clinical Trial page
- Check6 days agoNo Change Detected
- Check13 days agoNo Change Detected
- Check20 days agoChange DetectedThe record history now shows a new revision (v3.5.4) replacing the previous (v3.5.3). This reflects an update to the page's revision-tracking data.SummaryDifference0.1%

- Check27 days agoNo Change Detected
- Check34 days agoChange DetectedThe revision tag on the page history updated from v3.5.2 to v3.5.3, indicating a new release of the page's history metadata.SummaryDifference0.1%

- Check48 days agoChange DetectedRevision updated from v3.5.0 to v3.5.2 in the record history. This reflects a version change in the page’s interface rather than substantive trial data.SummaryDifference0.1%

- Check63 days agoChange DetectedThe sponsor field was updated from 'Karuna Therapeutics' to 'Karuna Therapeutics, Inc., a Bristol Myers Squibb company' to reflect the full corporate affiliation.SummaryDifference0.2%

- Check77 days agoChange DetectedRevision: v3.5.0 added and Revision: v3.4.3 removed in the Record History.SummaryDifference0.1%

- Check84 days agoChange DetectedA new revision entry v3.4.3 was added and the v3.4.2 entry was removed from the page history.SummaryDifference0.1%

Stay in the know with updates to KarXT Efficacy in Acute Schizophrenic Patients Clinical Trial
Enter your email address, and we'll notify you when there's something new on the KarXT Efficacy in Acute Schizophrenic Patients Clinical Trial page.